Patent Eligibility for Pharma, Biotech and Beyond: A Review and Discussion of the Mayo and Myriad Cases (live audio webcast)


Wednesday, October 3, 2012


Michael J. Kasdan, partner, Amster, Rothstein & Ebenstein LLP




noon EDT, duration 1 hr

CLE Credits:

1 hr


Join Michael J. Kasdan  as he discusses the impact of Mayo and Myriad in determining what pharmaceutical and biotechnology products and methods may be patented. And because Mayo and Myriad are also part of a larger wave of recent jurisprudence regarding patent-eligibility that has arisen in other fields, such as financial products, business methods, and computer software, our presenter also discusses the impact of these decisions on patent eligibility in other fields.